News and Announcements
Alcidion Appoint Resapp Health Co-Founder Brian Leedman
- Published July 28, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
28th July 2016, ASX Announcement
Alcidion Group Limited (ASX: ALC), a global leader in Clinical Informatics, today announced the appointment of Mr. Brian Leedman to the bord of the Company. This move comes at a pivotal time for Alcidion as the Company looks to expand market share of their award-winning Miya Platform product internationally.
Mr. Leedman is the co-founder of Resapp Health (ASX: RAP) where he currently serves in the role of the Executive Director and Vice President, Corporate Affairs. Mr Leedman is a marketing and investor relations professional with over 10 years’ experience in the biotechnology / healthcare industry. Prior to Resapp Helath, Mr. Leedman co-founded Enigma Therapeutics which listed on the ASX in 2013 as OncoSil Medical Limited.
Mr. Leedman previously served for 10 years as Vice President, Investor Relations for pSivida Corp. which is listed on the ASX and NASDAQ.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
